Tag Archive for: Optimum Perspectives Podcast

Weekly Roundup: Appointments and new perspectives

Hansa Biopharma appointed Adam Cutler as new Chief Financial Officer Hansa Biopharma AB announced the appointment of Adam Cutler as its new Chief Financial Officer (CFO) and member of the Executive Committee, effective June 22, 2026.  Adam succeeds Evan Ballantyne, who has served as CFO since 2024. Evan will continue in the role until June […]

Weekly roundup: Industry events, gender and GLP-1s, highlighting Rare Disease Day

Novo Nordisk Foundation announced it had awarded DKK 11.8 billion (€1.6 billion) during 2025 to support more than 2,200 projects aimed at improving people’s health and the sustainability of society and the planet. The projects cover the full range of the Foundation’s grant-giving areas, including key topics such as cardiometabolic diseases, antimicrobial resistance, the development of more resilient and climate-friendly […]

Weekly roundup: From awards and appointments to Women in Science Day and the launch of the European Life Sciences Coalition

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem The European Life Sciences Coalition (ELSC)  launched this week to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilising greater levels of private and public investment across the sector. Created in association with Invest Europe, the coalition brings together leading European life […]

Optimum’s chosen charity: Ariana Smiles

In October, at our 15th Annual Healthcare Investor Conference, we announced our chosen charity for the year, Ariana Smiles. Ariana Smiles is a Special Named Fund at the Children’s Cancer and Leukaemia Group, raising funds for research into precision oncology medicine for children with leukaemia. Stephanie Seales Gabbitas and her husband Chris set up Ariana […]

Verona Pharma: Preparing a potentially novel COPD medicine for market

A much-anticipated new potential drug for COPD moved a step closer to the market after Verona Pharma submitted its New Drug Application  to the U.S. FDA, seeking approval of ensifentrine as a maintenance therapy. In the latest episode of Optimum Perspectives podcast, Eva Haas caught up with Chris Martin, Senior Vice President of Commercial, who […]

© Optimum Strategic Communications.